Trial Profile
Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 05 Dec 2023 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 16 Dec 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2022.